Curaleaf And Aurora Are Now Sniping At Each Other

Curaleaf and Aurora Cannabis have engaged in a heated exchange of public statements over Curaleaf's hostile takeover bid. On Monday, the two companies traded press releases, with both CEOs amplifying their criticisms. Aurora cautioned shareholders that Curaleaf's bid contained inaccurate statements about Aurora's business and urged them to take no action while its special committee reviews the offer.

The proposed takeover is centered around Aurora's EU-GMP certified cannabis cultivation facilities, which are crucial for growth in the European market. Curaleaf is offering a premium on Aurora's average share price, making the deal an appealing proposition for Aurora's shareholders. However, Aurora's CEO, Miguel Martin, argues that Curaleaf's timing and public comments are an attempt to pressure shareholders into a short-term decision.

Aurora disputes Curaleaf's claims about its German business, stating that the flagged reimbursement segment makes up less than 10% of German volume before regulatory changes. The company also highlighted its August 19 UK acquisitions and its top market share in Poland. Despite the recent drop in Aurora's share price, Curaleaf's CEO, Boris Jordan, maintains that Aurora's protests and statistics are misleading.